|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
We further show that IDE is more oxidized in the hippocampus compared to the cerebellum of AD patients.
|
15708439 |
2005 |
|
Alzheimer's Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Three IDE variants were associated with AD within epsilon4-negative subjects (genotype exact test P-values < or =0.02).
|
12809979 |
2003 |
|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
As for Alzheimer's disease (AD) related pathology, chia seed not only increased α-secretase such as ADAM10 and insulin degrading enzyme (IDE), but also increased β-secretase including beta-secretase 1 (BACE1) and cathepsin B, with an overall effects of elevation in the hippocampal Aβ<sub>42</sub> level; chia seed slightly reduced p-Tauser404 in the hippocampus; while an elevation in neuro-inflammation with the activation of glial fibrillary acidic protein (GFAP) and Ibα-1 were observed post chia seed supplementation.
|
30110883 |
2018 |
|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
In the Tg2576 mouse model of Alzheimer's disease, UE2316 treatment of mice aged 14 months for 4 weeks also decreased the number of β-amyloid (Aβ) plaques in the cerebral cortex, associated with a selective increase in local insulin-degrading enzyme (involved in Aβ breakdown and known to be glucocorticoid regulated).
|
26305888 |
2015 |
|
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Protein levels of insulin-degrading enzyme (IDE), which is linked to insulin signaling and degrades Aβ, significantly increased in the 3xTg-AD mice brain compared with non-transgenic mice, and were further increased by APO.
|
28550243 |
2017 |
|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Further studies of the role of IDE in the pathogenesis of AD, which may uncover potential treatment target, are much needed.
|
16399206 |
2006 |
|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
In addition to suggesting research targets such as the IDE and SORCS1 genes, which are implicated in both AD and diabetes, LEARn suggests specific mechanisms for pre-disease remediation, based on nutritional adjustment of aberrant DNA methylation and oxidation.
|
22555376 |
2012 |
|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
These findings show that reduced IDE expression is associated with a significant risk factor for AD and suggest that IDE may interact with APOE status to affect Abeta metabolism.
|
12507914 |
2003 |
|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
We studied the effects of TSA on the levels of gelsolin; amyloid precursor protein (APP); proteolytic enzymes (γ-secretase and β-secretase) responsible for the production of Aβ; Aβ-cleaving enzymes, i.e., neprilysin (NEP) and insulin-degrading enzyme (IDE); and amyloid load in the double transgenic (Tg) APPswe/PS1(δE9) mouse model of AD.
|
25387339 |
2014 |
|
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Based on our SNP and haplotype results, we delineate the model that IDE promoter and 3' untranslated region/downstream variation may have different effects on IDE expression, presumably a relevant endophenotype with disorder-specific effects on AD and T2DM susceptibility.
|
22107728 |
2011 |
|
Alzheimer's Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Discovery by the Epistasis Project of an epistatic interaction between the GSTM3 gene and the HHEX/IDE/KIF11 locus in the risk of Alzheimer's disease.
|
23036584 |
2013 |
|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Insulin degrading enzyme contributes to the pathology in a mixed model of Type 2 diabetes and Alzheimer's disease: possible mechanisms of IDE in T2D and AD.
|
29222348 |
2018 |
|
Alzheimer's Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, the findings of our study suggest that the two IDE polymorphisms considered in the analysis do not appear to play a major role in DS-related AD.
|
15911128 |
2005 |
|
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In contrast to the human data, the commonly used APPswePS1dE9 and 3xTg-AD mouse models do not show altered Aβ degradation and IDE levels with AD progression, raising doubts whether mouse models that overproduce Aβ peptides are representative for human sAD.
|
23534431 |
2013 |
|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease.
|
17760499 |
2007 |
|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
One hypothesis is that the link between DM and AD is related to the function of insulin-degrading enzyme (IDE), an enzyme that degrades not only insulin and pancreatic amylin but also beta-amyloid (Abeta).
|
18346114 |
2009 |
|
Alzheimer's Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Research has suggested that variations within the IDE/HHEX gene region may underlie the association of type 2 diabetes with Alzheimer disease (AD).
|
26173052 |
2015 |
|
Alzheimer's Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Concordant association of insulin degrading enzyme gene (IDE) variants with IDE mRNA, Abeta, and Alzheimer's disease.
|
20098734 |
2010 |
|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
In the present study, we measured plasma levels of amyloid-β1-42(0.142±0.029μg/L)and furin(2.292±1.54μg/L), together with those of the metalloproteinases, insulin-degrading enzyme(1.459±1.14μg/L) and neprilysin(0.073±0.015μg/L), in order to develop biomarkers for AD.
|
28719622 |
2017 |
|
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
However, IDE mRNA was higher in cortex of AD cases (SMD = 0.71, 95% CI [0.14, 1.29], p = 0.01), not in hippocampus (SMD = -0.26, 95% CI [-0.58, 0.06]).
|
29357797 |
2018 |
|
Alzheimer's Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Previously some studies have examined the role of common variation in the IDE gene with AD risk but the results have been inconsistent.
|
16914266 |
2006 |
|
Alzheimer's Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
A single nucleotide polymorphism (SNP) in the insulin degrading enzyme gene (IDE), rs3781239, showed a significant association with AD.
|
20880607 |
2012 |
|
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Neprilysin levels were not different in AD liver samples, while cathepsin D and insulin-degrading enzyme were significantly altered in AD subjects.
|
30192871 |
2018 |
|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our findings have relevance for the emerging genetic evidence suggesting that IDE may be a late-onset AD-risk gene, and for the epidemiological relationships among hyperinsulinemia, DM2, and AD.
|
15039230 |
2004 |
|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
The mechanism of IDE catalyzed degrading of Aβ peptides, which is of fundamental importance in the design of therapeutic methods for Alzheimer's disease, has not been fully understood.
|
30133282 |
2018 |